Literature DB >> 9245707

Suppression of tumor growth with recombinant murine angiostatin.

Z Wu1, M S O'Reilly, J Folkman, Y Shing.   

Abstract

Angiostatin, a 38 kDa internal fragment of plasminogen, is an antiangiogenic endothelial cell inhibitor. It regresses several primary and metastatic tumors in mice. To produce recombinant angiostatin for further structural and functional studies, the mouse angiostatin gene preceded by a sequence including a signal peptide of plasminogen was introduced into baculovirus. Recombinant murine angiostatin was purified from the culture medium of angiostatin baculovirus-infected insect cells (yield = 1 mg/liter) with a single-step of lysine-Sepharose chromatography. The angiostatin baculovirus-infected insect cells expressed and secreted a 52 kDa polypeptide that demonstrated all of the biological activities of angiostatin. A partial amino acid sequence of the NH2-terminus of the secreted protein revealed that the signal peptide was recognized and properly cleaved in insect cells. The recombinant murine angiostatin potently inhibited the proliferation of bovine capillary endothelial cells in vitro (half maximal inhibition = 50 ng/ml) and suppressed the growth of primary Lewis lung carcinoma in vivo (6 mg/kg/day, T/C = 0.08).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9245707     DOI: 10.1006/bbrc.1997.7032

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

Review 1.  Gene therapy for carcinoma of the breast.

Authors:  M A Stoff-Khalili; P Dall; D T Curiel
Journal:  Cancer Gene Ther       Date:  2006-01-06       Impact factor: 5.987

Review 2.  Preventing the aortic complications of Marfan syndrome: a case-example of translational genomic medicine.

Authors:  Alain Li-Wan-Po; Bart Loeys; Peter Farndon; David Latham; Caroline Bradley
Journal:  Br J Clin Pharmacol       Date:  2011-07       Impact factor: 4.335

Review 3.  Angiogenesis in ovarian cancer: molecular pathology and therapeutic strategies.

Authors:  Pamela J Paley
Journal:  Curr Oncol Rep       Date:  2002-03       Impact factor: 5.075

Review 4.  Angiogenesis, metastasis, and endogenous inhibition.

Authors:  M Kirsch; G Schackert; P M Black
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

5.  Adenoviral vector expressing murine angiostatin inhibits a model of breast cancer metastatic growth in the lungs of mice.

Authors:  S Gyorffy; K Palmer; J Gauldie
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

6.  Adeno-associated virus type-2 expression of pigmented epithelium-derived factor or Kringles 1-3 of angiostatin reduce retinal neovascularization.

Authors:  Brian J Raisler; Kenneth I Berns; Maria B Grant; Denis Beliaev; William W Hauswirth
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-18       Impact factor: 11.205

7.  Serum levels of angiogenic and anti-angiogenic factors: their prognostic relevance in locally advanced hepatocellular carcinoma.

Authors:  Bal Krishan Sharma; Radhika Srinivasan; Shweta Kapil; Bhupesh Singla; Nitin Saini; Yogesh Kumar Chawla; Anuradha Chakraborti; Ajay Duseja; Naveen Kalra; Radha Krishan Dhiman
Journal:  Mol Cell Biochem       Date:  2013-08-04       Impact factor: 3.396

8.  Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin.

Authors:  S Cha; E A Knopp; G Johnson; A Litt; J Glass; M L Gruber; S Lu; D Zagzag
Journal:  AJNR Am J Neuroradiol       Date:  2000-05       Impact factor: 4.966

Review 9.  Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor.

Authors:  Z Zhu; L Witte
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.651

10.  Angiostatin-mediated suppression of cancer metastases by primary neoplasms engineered to produce granulocyte/macrophage colony-stimulating factor.

Authors:  Z Dong; J Yoneda; R Kumar; I J Fidler
Journal:  J Exp Med       Date:  1998-08-17       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.